Postmarketing CellCept Data Prompt Stronger Pregnancy Alert

Postmarketing reports of an increased risk of first trimester loss and congenital malformations associated with the use of mycophenolate mofetil during pregnancy has prompted a pregnancy category label change for the immunosuppressant drug.